早期海马保护预防性颅脑照射对局限期小细胞肺癌神经认知功能的影响:多中心2期试验(SAKK 15/12)
这项多中心2期试验评估局限期小细胞肺癌患者在接受早期海马保护预防性颅脑照射后的神经认知功能与临床结局。44例入组患者中38例在照射后6个月可评估神经认知功能,6个月和12个月无神经认知功能下降的比例分别为34.2%和48.5%。结论认为该比例与序贯非海马保护预防性颅脑照射相似,但早期海马保护预防性颅脑照射可行且脑转移无生存期与总生存期令人鼓舞。
要点
- 6个月无神经认知功能下降比例为34.2%,12个月为48.5%
- 12个月脑转移无生存期84.2%,总生存期87.7%
- 早期海马保护预防性颅脑照射可行,但神经认知功能未见优于序贯非海马保护照射
核心结论
- 早期海马保护预防性颅脑照射后6个月和12个月无神经认知功能下降的比例与序贯非海马保护预防性颅脑照射相似,未见更优。
- 早期海马保护预防性颅脑照射在局限期小细胞肺癌中可行,且该选定人群的脑转移无生存期与总生存期令人鼓舞。
研究设计与样本
- 多中心2期试验纳入局限期小细胞肺癌患者,在海马保护预防性颅脑照射与第二周期化疗及胸部放疗同期进行。
- 所有患者在基线、照射后6周、6个月和12个月接受客观神经认知功能测试,主要终点为照射后6个月神经认知功能下降。
- 试验假设无神经认知功能下降患者比例≤30%为不 promising。
主要发现
- 44例入组患者中38例在照射后6个月有可评估的神经认知功能评估。
- 可评估患者中6个月和12个月无神经认知功能下降的比例分别为34.2%(90%CI 21.6-48.8)和48.5%(95%CI 30.8-66.5)。
- 中位随访13.2个月(95%CI 12.6-14.1),12个月时脑转移无生存期为84.2%,总生存期为87.7%(95%CI 73.0-94.7)。
- 4例死于小细胞肺癌,1例死于呼吸衰竭,1例死于出血,1例死因不明。
- 最常见≥3级急性不良事件为贫血(21.4%)、发热性中性粒细胞减少(19.1%)和乏力(14.3%)。
临床怎么用
- 早期海马保护预防性颅脑照射可作为局限期小细胞肺癌的可行治疗选择,但需告知患者神经认知功能保护未显示优于序贯非海马保护照射。
- 治疗期间应关注贫血、发热性中性粒细胞减少和乏力等≥3级急性不良事件。
局限性
- 2期试验样本量有限,入组44例,仅38例有6个月可评估神经认知功能数据。
- 中位随访仅13.2个月,长期神经认知功能与生存结局需更长时间随访。
- 无同期非海马保护对照组,神经认知功能比较基于历史观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to evaluate neurocognitive function (NCF) and clinical outcomes after early hippocampal avoidance (HA) prophylactic cranial irradiation (PCI) in limited disease (LD) small cell lung cancer (SCLC). METHODS AND MATERIALS: In a phase 2 trial, patients with LD SCLC received HA-PCI concomitant with the second cycle of chemotherapy and thoracic radiation therapy. All patients underwent objective NCF testing at baseline, 6 weeks, and 6 and 12 months after HA-PCI. NCF tests included Hopkins Verbal Learning Test Revised, Controlled Oral Word Association, and Trail Making Tests A and B. The primary endpoint was NCF decline at 6 months after HA-PCI. We assumed ≤30% of patients with no NCF decline to be unpromising. Secondary endpoints included brain metastases-free survival (BMFS), overall survival (OS), and safety of the concomitant treatment. RESULTS: Among the 44 patients enrolled in the trial, 38 had evaluable NCF assessment at 6 months after HA-PCI. The proportion of evaluable patients showing no NCF decline at 6 and 12 months was 34.2% (90% confidence interval [CI], 21.6-48.8) and 48.5% (95% CI, 30.8-66.5), respectively. Median follow-up was 13.2 months (95% CI, 12.6-14.1). At 12 months, BMFS was 84.2% and OS was 87.7% (95% CI, 73.0-94.7). Four patients died of SCLC, 1 of respiratory failure, 1 of hemorrhage, and 1 for unknown reason. The most frequently reported grade ≥3 acute adverse events were anemia (21.4%), febrile neutropenia (19.1%), and fatigue (14.3%). CONCLUSIONS: The proportion of patients showing no NCF decline 6 and 12 months after early HA-PCI does not appear to be better than, but rather similar to, that observed in patients receiving sequential PCI without HA. Early HA-PCI in LD SCLC is feasible, with observation of promising BMFS and OS in this selected population.
引用
- Vees H, Caparrotti F, Eboulet EI, et al. Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12). Int J Radiat Oncol Biol Phys. 2020. PMID: 32142869. doi:10.1016/j.ijrobp.2020.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。